ATE257471T1 - Verwendung von imidazol-derivaten zur behandlung von beschwerden an denen angiotensin rezeptoren at1 und at2 beteiligt sind, diese verbindungen, deren herstellung, verwendung als medikamente, und pharmazeutische zusammensetzungen die sie enthalten - Google Patents

Verwendung von imidazol-derivaten zur behandlung von beschwerden an denen angiotensin rezeptoren at1 und at2 beteiligt sind, diese verbindungen, deren herstellung, verwendung als medikamente, und pharmazeutische zusammensetzungen die sie enthalten

Info

Publication number: ATE257471T1
Authority: AT; Austria
Prior art keywords: aryl; alkyl; alkenyl; medications; compounds
Prior art date: 1994-03-04

Application number

AT95910603T

Other languages

English (en)

Inventor

Alain Corbier

Pierre Deprez

Michel Fortin

Jacques Guillaume

Bertrand Heckmann

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-04

Filing date

1995-02-27

Publication date

2004-01-15

1995-02-27 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2004-01-15 Application granted granted Critical

2004-01-15 Publication of ATE257471T1 publication Critical patent/ATE257471T1/de

Links

RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title abstract 4
102000008873 Angiotensin II receptor Human genes 0.000 title abstract 2
108050000824 Angiotensin II receptor Proteins 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
125000003118 aryl group Chemical group 0.000 abstract 7
125000000217 alkyl group Chemical group 0.000 abstract 6
125000003342 alkenyl group Chemical group 0.000 abstract 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000004414 alkyl thio group Chemical group 0.000 abstract 2
-1 alkylpiperazinyl Chemical group 0.000 abstract 2
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 abstract 1
230000002159 abnormal effect Effects 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
125000005110 aryl thio group Chemical group 0.000 abstract 1
125000004104 aryloxy group Chemical group 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 1
125000002757 morpholinyl group Chemical group 0.000 abstract 1
125000004193 piperazinyl group Chemical group 0.000 abstract 1
125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
125000001422 pyrrolinyl group Chemical group 0.000 abstract 1
125000000168 pyrrolyl group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000000638 stimulation Effects 0.000 abstract 1
125000001174 sulfone group Chemical group 0.000 abstract 1
125000004434 sulfur atom Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/68—Halogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT95910603T 1994-03-04 1995-02-27 Verwendung von imidazol-derivaten zur behandlung von beschwerden an denen angiotensin rezeptoren at1 und at2 beteiligt sind, diese verbindungen, deren herstellung, verwendung als medikamente, und pharmazeutische zusammensetzungen die sie enthalten ATE257471T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9402518A FR2716882B1 (fr)	1994-03-04	1994-03-04	Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
PCT/FR1995/000228 WO1995023792A1 (fr)	1994-03-04	1995-02-27	Utilisation de derives de l'imidazole au traitement d'affections impliquant les recepteurs at1 et at2 de l'angiotensine, certains de ces produits, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant

Publications (1)

Publication Number	Publication Date
ATE257471T1 true ATE257471T1 (de)	2004-01-15

Family

ID=9460689

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95910603T ATE257471T1 (de)	1994-03-04	1995-02-27	Verwendung von imidazol-derivaten zur behandlung von beschwerden an denen angiotensin rezeptoren at1 und at2 beteiligt sind, diese verbindungen, deren herstellung, verwendung als medikamente, und pharmazeutische zusammensetzungen die sie enthalten

Country Status (16)

Country	Link
US (2)	US5811445A (de)
EP (2)	EP1233015A1 (de)
JP (1)	JP3881374B2 (de)
KR (1)	KR100369425B1 (de)
CN (1)	CN1146765A (de)
AT (1)	ATE257471T1 (de)
AU (1)	AU704897B2 (de)
CA (1)	CA2184111A1 (de)
DE (1)	DE69532412T2 (de)
DK (1)	DK0748315T3 (de)
ES (1)	ES2210285T3 (de)
FR (1)	FR2716882B1 (de)
HU (1)	HUT75697A (de)
PT (1)	PT748315E (de)
RU (1)	RU2141321C1 (de)
WO (1)	WO1995023792A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2716882B1 (fr) *	1994-03-04	1996-04-05	Roussel Uclaf	Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
FR2716883B1 (fr) *	1994-03-04	1996-04-26	Roussel Uclaf	Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
EP0855392A3 (de)	1997-01-22	2000-01-05	Hoechst Aktiengesellschaft	Fünfgliedrige Heterocyclen mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19731328A1 (de) *	1997-07-22	1999-01-28	Hoechst Ag	Imidazol-Derivate mit Biphenylsulfonylcyanamid-Seitenkette, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19832428A1 (de) *	1998-07-18	2000-01-20	Hoechst Marion Roussel De Gmbh	Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832429A1 (de) *	1998-07-18	2000-01-20	Hoechst Marion Roussel De Gmbh	Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CN1304000C (zh) *	1998-12-23	2007-03-14	诺瓦提斯公司	缬沙坦在制备用于治疗肺癌的药物中的用途
EP1013273A1 (de) *	1998-12-23	2000-06-28	Novartis AG	Verwendung von AT-1 Rezeptorantagonisten oder AT-2 Rezeptormodulatoren zur Behandlung von Erkrankungen, die mit einer Erhöhung an AT-1 oder AT-2 Rezeptoren verbunden sind
US6465502B1 (en)	1998-12-23	2002-10-15	Novartis Ag	Additional therapeutic use
CN101011390A (zh)	1999-01-26	2007-08-08	诺瓦提斯公司	血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
IL144216A0 (en) *	1999-01-26	2002-05-23	Novartis Ag	Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
US6548529B1 (en) *	1999-04-05	2003-04-15	Bristol-Myers Squibb Company	Heterocyclic containing biphenyl aP2 inhibitors and method
YU78601A (sh) *	1999-05-05	2005-07-19	Aventis Pharma Deutschland Gmbh.	1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
DE10030087B4 (de) *	2000-06-19	2007-01-18	Boehringer Werkzeugmaschinen Gmbh	Verfahren und Vorrichtung zum Vermessen und Bearbeiten von Werkstücken
CN1529697B (zh)	2001-05-31	2010-09-22	维科尔药物公司	用作血管紧张素ⅱ激动剂的三环化合物
CN101284773A (zh) *	2001-08-09	2008-10-15	小野药品工业株式会社	羧酸衍生物及以它为活性成分的药剂
PE20040167A1 (es) *	2002-03-28	2004-05-26	Novartis Ag	Amidas del acido sulfamico
MXPA06002064A (es) *	2003-10-20	2006-05-19	Solvay Pharm Bv	Derivados e 1h imidazol como moduladores del receptor cannabinoide.
CA2617055A1 (en) *	2005-07-29	2007-02-08	Bayer Healthcare Llc	Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
EP2297113A1 (de) *	2008-04-29	2011-03-23	Theravance, Inc.	Blutdrucksenkende mittel mit dualer wirkung
EP2455388A1 (de)	2010-11-23	2012-05-23	LanthioPep B.V.	Neuartige Rezeptoragonisten von Angiotensin des Typs 2 (AT2) und Verwendungen dafür
RU2475243C1 (ru) *	2012-02-16	2013-02-20	Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН)	Средство, обладающее антигипертензивной активностью
EP4007592A1 (de)	2019-08-02	2022-06-08	LanthioPep B.V.	Rezeptoragonisten von angiotensin typ 2 (at2) zur behandlung von krebs
GB2605148A (en) *	2021-03-23	2022-09-28	Vicore Pharma Ab	New compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR465368A (fr) *	1912-11-28	1914-04-15	Franz Roemer	Procédé et appareil pour le séchage de placages et autres objets ayant la forme de feuilles ou de lames
SU1598877A3 (ru) *	1986-12-31	1990-10-07	Жансен Фармасетика Н.В. (Фирма)	Способ получени производных 5-имидазолкарбоновой кислоты, или их стереоизомеров, или их солей
CA1338238C (en) *	1988-01-07	1996-04-09	David John Carini	Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
EP0409332A3 (en) *	1989-07-19	1991-08-07	Merck & Co. Inc.	Substituted triazoles as angiotensin ii antagonists
ES1011809Y (es) *	1989-10-23	1991-08-01	Minano Iglesias Jesus	Muneco-envase.
DE3937182A1 (de) *	1989-11-08	1991-05-16	Bosch Gmbh Robert	Verfahren zur bearbeitung der oberflaeche von plankommutatoren
IL98319A (en) *	1990-07-05	1997-04-15	Roussel Uclaf	Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them
US5126342A (en) *	1990-10-01	1992-06-30	Merck & Co., Inc.	Imidazole angiotensin ii antagonists incorporating acidic functional groups
CA2093125C (en) *	1990-10-02	2003-12-16	Warner-Lambert Company	Angiotensin ii antagonists
CA2058198A1 (en) *	1991-01-04	1992-07-05	Adalbert Wagner	Azole derivatives, process for their preparation, and their use
EP0505098A1 (de) *	1991-03-19	1992-09-23	Merck & Co. Inc.	Imidazolderivate mit funktionelle Säuregruppen als Angiotensin-II-Antagoniste
TW215434B (de) *	1992-03-07	1993-11-01	Hoechst Ag
EP0577023A3 (en) *	1992-07-01	1996-12-18	Hoechst Ag	Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
EP0577025A3 (de) *	1992-07-01	1998-02-04	Hoechst Aktiengesellschaft	Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen
JP3309438B2 (ja) *	1992-09-04	2002-07-29	日本ゼオン株式会社	ブロック共重合体
FR2711367B1 (fr) *	1993-10-19	1995-12-01	Roussel Uclaf	Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus.
US5395844A (en) *	1993-06-10	1995-03-07	The Du Pont Merck Pharmaceutical Company	Imidazole 5-position substituted angiotensin II antagonists
FR2716882B1 (fr) *	1994-03-04	1996-04-05	Roussel Uclaf	Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.

1994
- 1994-03-04 FR FR9402518A patent/FR2716882B1/fr not_active Expired - Fee Related
1995
- 1995-02-27 CN CN95192744A patent/CN1146765A/zh active Pending
- 1995-02-27 CA CA002184111A patent/CA2184111A1/fr not_active Abandoned
- 1995-02-27 HU HU9602414A patent/HUT75697A/hu unknown
- 1995-02-27 PT PT95910603T patent/PT748315E/pt unknown
- 1995-02-27 AT AT95910603T patent/ATE257471T1/de not_active IP Right Cessation
- 1995-02-27 KR KR1019960704848A patent/KR100369425B1/ko not_active Expired - Fee Related
- 1995-02-27 EP EP02006541A patent/EP1233015A1/de not_active Withdrawn
- 1995-02-27 EP EP95910603A patent/EP0748315B1/de not_active Expired - Lifetime
- 1995-02-27 WO PCT/FR1995/000228 patent/WO1995023792A1/fr not_active Ceased
- 1995-02-27 AU AU18524/95A patent/AU704897B2/en not_active Ceased
- 1995-02-27 ES ES95910603T patent/ES2210285T3/es not_active Expired - Lifetime
- 1995-02-27 JP JP52272795A patent/JP3881374B2/ja not_active Expired - Fee Related
- 1995-02-27 DE DE69532412T patent/DE69532412T2/de not_active Expired - Fee Related
- 1995-02-27 US US08/700,468 patent/US5811445A/en not_active Expired - Fee Related
- 1995-02-27 RU RU96120211A patent/RU2141321C1/ru active
- 1995-02-27 DK DK95910603T patent/DK0748315T3/da active
1998
- 1998-06-01 US US09/088,156 patent/US5977155A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US5977155A (en)	1999-11-02
US5811445A (en)	1998-09-22
CN1146765A (zh)	1997-04-02
KR970701700A (ko)	1997-04-12
FR2716882A1 (fr)	1995-09-08
PT748315E (pt)	2004-05-31
JPH09509926A (ja)	1997-10-07
JP3881374B2 (ja)	2007-02-14
HUT75697A (en)	1997-05-28
DK0748315T3 (da)	2004-03-15
HU9602414D0 (en)	1996-11-28
FR2716882B1 (fr)	1996-04-05
EP0748315A1 (de)	1996-12-18
EP1233015A1 (de)	2002-08-21
WO1995023792A1 (fr)	1995-09-08
DE69532412T2 (de)	2004-10-07
RU2141321C1 (ru)	1999-11-20
DE69532412D1 (de)	2004-02-12
EP0748315B1 (de)	2004-01-07
KR100369425B1 (ko)	2003-05-22
AU1852495A (en)	1995-09-18
CA2184111A1 (fr)	1995-09-08
ES2210285T3 (es)	2004-07-01
AU704897B2 (en)	1999-05-06

Legal Events

Date	Code	Title	Description
2004-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE257471T1 (de)	2004-01-15	Verwendung von imidazol-derivaten zur behandlung von beschwerden an denen angiotensin rezeptoren at1 und at2 beteiligt sind, diese verbindungen, deren herstellung, verwendung als medikamente, und pharmazeutische zusammensetzungen die sie enthalten
ATE334973T1 (de)	2006-08-15	Chinazolinverbindungen
DE69406903D1 (de)	1998-01-02	3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel
ATE125257T1 (de)	1995-08-15	Azaindole, deren herstellungsverfahren und sie enthaltende arzneimittel.
HUT50163A (en)	1989-12-28	Process for production of derivatives of indole and medical compositions containing them as active substance
BR9812239A (pt)	2000-07-18	Composto, formulação farmacêutica, uso do composto, processos para o tratamento de distúrbios, para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e, para a preparação do composto
BG110211A (en)	2009-02-27	SUBSTITUTED PHENIPIPERAZASES AS MODULATORS OF DOPAMIN NEUROTRANSMISSION
ES2142861T3 (es)	2000-05-01	Derivados de 4-(1h-2-metilimidazo(4,5-c)piridinilmetil)fenilsulfonamida como antagonistas del paf.
GEP20002069B (en)	2000-05-10	Taxoid Based Pharmaceutical Compositions and Method for its Production
AR006360A1 (es)	1999-08-25	Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion.
ATE172726T1 (de)	1998-11-15	7-(2-aminoethyl)-benzothiazolone
NO307464B1 (no)	2000-04-10	Galantaminderivater, farmasøytisk sammensetning inneholdende samme samt deres anvendelse for fremstilling av medikamenter
DE69312567D1 (de)	1997-09-04	2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel
DE69417573D1 (de)	1999-05-06	Tricyclische derivate und phamazeutische zusammensetzungen die sie enthalten
DE69612540D1 (de)	2001-05-23	Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von Krankheiten in Zusammenhang mit aktivem Sauestoff und freien Radikalen
DE69828516D1 (de)	2005-02-10	(hetero)aryl-sulfonamid derivate, deren herstellung und deren verwenddung als faktor xa inhibitoren
AR029302A1 (es)	2003-06-25	Compuesto de fenilo 1,4-sustituido, el uso del mismo para la manufactura de un medicamento, agente de diagnostico, composicion farmaceutica que lo contiene y proceso para su preparacion
ATE169635T1 (de)	1998-08-15	Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen
ATE25387T1 (de)	1987-02-15	Synergistine derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
FI102065B1 (fi)	1998-10-15	Menetelmä valmistaa terapeuttisesti aktiivisia 2-amino-4-morfolino-6-propyyli-1,3,5-triatsiineja
DE69735008D1 (de)	2006-02-02	Polyhydroxyphenolderivate und mittel zur vorbeugung und therapie von knochen- und knorpelkrankheiten die diese enthalten
TH51750A (th)	2002-07-02	อนุพันธ์โครแมนที่ถูกแทนที่
HUT57749A (en)	1991-12-30	Process for producing pharmaceutical compositions suitable for treating pathological conditions concerning cerebral blood insufficiency and one special active ingredient
FR2407910A1 (fr)	1979-06-01	Nouveau derive de bis-(2-hydroxy-3-nitrophenyl)-methane, son procede de production et composition pharmaceutique le contenant
TH9834A (th)	1991-11-01	อนุพันธ์ 2-ออกโซ-3, 8-ไดแอซาสไพโร [4, 5] -เดเคนที่แปลกใหม่สารผสมทางเภสัชกรรมที่มีอนุพันธ์เหล่านี้และกรรมวิธีเพื่อการเตรียมสารเหล่านี้